Wedbush Expects Weaker Earnings for Voyager Therapeutics

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Equities research analysts at Wedbush reduced their Q1 2025 earnings per share estimates for shares of Voyager Therapeutics in a research report issued on Wednesday, March 12th. Wedbush analyst Y. Zhong now anticipates that the company will earn ($0.37) per share for the quarter, down from their previous estimate of ($0.27). Wedbush currently has a “Outperform” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. Wedbush also issued estimates for Voyager Therapeutics’ Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.50) EPS, FY2026 earnings at ($1.32) EPS, FY2027 earnings at ($0.93) EPS, FY2028 earnings at ($0.88) EPS and FY2029 earnings at ($0.87) EPS.

Several other analysts also recently weighed in on VYGR. Cantor Fitzgerald reissued an “overweight” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Canaccord Genuity Group reduced their price objective on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, March 13th. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday, March 13th. Citigroup began coverage on shares of Voyager Therapeutics in a report on Monday, December 2nd. They issued a “buy” rating and a $12.00 target price on the stock. Finally, Wells Fargo & Company set a $10.00 price target on shares of Voyager Therapeutics and gave the stock an “overweight” rating in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Voyager Therapeutics currently has a consensus rating of “Buy” and an average price target of $14.86.

Voyager Therapeutics Trading Down 0.3 %

Shares of Voyager Therapeutics stock opened at $3.89 on Monday. Voyager Therapeutics has a 12-month low of $3.56 and a 12-month high of $10.66. The stock has a market cap of $212.50 million, a price-to-earnings ratio of 5.48 and a beta of 0.99. The company has a fifty day simple moving average of $4.79 and a 200-day simple moving average of $5.80.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $4.39 million during the quarter, compared to analyst estimates of $16.58 million. During the same period last year, the company earned $1.25 earnings per share.

Institutional Trading of Voyager Therapeutics

Several hedge funds have recently modified their holdings of the business. Cubist Systematic Strategies LLC acquired a new position in Voyager Therapeutics during the fourth quarter worth $29,000. Tower Research Capital LLC TRC grew its stake in shares of Voyager Therapeutics by 133.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after purchasing an additional 3,077 shares during the period. Picton Mahoney Asset Management increased its holdings in shares of Voyager Therapeutics by 71.1% in the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock valued at $33,000 after purchasing an additional 2,444 shares in the last quarter. Oxford Asset Management LLP purchased a new position in shares of Voyager Therapeutics in the 4th quarter valued at about $60,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Voyager Therapeutics in the third quarter valued at about $74,000. 48.03% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the sale, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders sold 10,778 shares of company stock worth $58,548. 4.53% of the stock is owned by insiders.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.